UY39786A - Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades - Google Patents
Derivados de Triazolopirimidina y su uso en el Tratamiento de EnfermedadesInfo
- Publication number
- UY39786A UY39786A UY0001039786A UY39786A UY39786A UY 39786 A UY39786 A UY 39786A UY 0001039786 A UY0001039786 A UY 0001039786A UY 39786 A UY39786 A UY 39786A UY 39786 A UY39786 A UY 39786A
- Authority
- UY
- Uruguay
- Prior art keywords
- diseases
- treatment
- compounds
- triazolopyrimidine derivatives
- triazolopyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona un compuesto, o una sal farmacéuticamente aceptable del mismo, de la fórmula (I): (I) en donde R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K y A han sido descriptos en la presente, usos terapéuticos de dichos compuestos, usos de dichos compuestos como químicos de investigación, una composición farmacéutica y combinaciones que comprenden dichos compuestos, y métodos para elaborar los compuestos de la invención.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021096104 | 2021-05-26 | ||
| CN2022085537 | 2022-04-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY39786A true UY39786A (es) | 2023-01-31 |
Family
ID=82019774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001039786A UY39786A (es) | 2021-05-26 | 2022-05-24 | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11878973B2 (es) |
| EP (1) | EP4347596A1 (es) |
| JP (2) | JP7753397B2 (es) |
| KR (1) | KR20240013168A (es) |
| CN (1) | CN117425657A (es) |
| AR (1) | AR125966A1 (es) |
| AU (1) | AU2022279728A1 (es) |
| BR (1) | BR112023024551A2 (es) |
| CA (1) | CA3219799A1 (es) |
| CL (1) | CL2023003489A1 (es) |
| CO (1) | CO2023018119A2 (es) |
| CR (1) | CR20230616A (es) |
| DO (1) | DOP2023000256A (es) |
| EC (1) | ECSP23095674A (es) |
| IL (1) | IL308229A (es) |
| JO (1) | JOP20230304A1 (es) |
| MX (1) | MX2023013892A (es) |
| PE (1) | PE20240587A1 (es) |
| PH (1) | PH12023553140A1 (es) |
| PY (1) | PY2240956A (es) |
| TW (1) | TW202313616A (es) |
| UY (1) | UY39786A (es) |
| WO (1) | WO2022249060A1 (es) |
| ZA (1) | ZA202310237B (es) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210371855A1 (en) * | 2018-06-15 | 2021-12-02 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| UY40470A (es) * | 2022-10-12 | 2024-05-15 | Novartis Ag | Compuestos tricíclicos y sus usos |
| WO2024105553A1 (en) * | 2022-11-16 | 2024-05-23 | Novartis Ag | Bicyclic heterocycles and their use as wrn inhibitors |
| WO2024105610A1 (en) | 2022-11-18 | 2024-05-23 | Novartis Ag | Pharmaceutical combinations and uses thereof |
| EP4622976A1 (en) | 2022-11-23 | 2025-10-01 | Novartis AG | Solid forms of a fused pyridine for the treamtent of cancer |
| EP4630426A2 (en) * | 2022-12-05 | 2025-10-15 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Triazole compounds, preparation methods and medicinal uses thereof |
| KR20250123932A (ko) | 2022-12-30 | 2025-08-18 | 수조우 푸허 바이오파마 컴퍼니 리미티드 | Wrn 억제제 |
| CN118271322A (zh) * | 2022-12-30 | 2024-07-02 | 苏州浦合医药科技有限公司 | Wrn解旋酶抑制剂 |
| WO2024153155A1 (zh) * | 2023-01-18 | 2024-07-25 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| WO2024155884A1 (en) * | 2023-01-20 | 2024-07-25 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
| WO2024153244A1 (zh) * | 2023-01-20 | 2024-07-25 | 南京再明医药有限公司 | 含氮类化合物 |
| WO2024187049A1 (en) * | 2023-03-08 | 2024-09-12 | Synnovation Therapeutics, Inc. | Heterocyclic compounds as wrn inhibitors |
| WO2024193716A1 (zh) * | 2023-03-17 | 2024-09-26 | 南京再明医药有限公司 | 三唑并嘧啶类化合物 |
| CN120858096A (zh) * | 2023-03-23 | 2025-10-28 | 北京丹擎医药科技有限公司 | 双环衍生物及其组合物和应用 |
| KR20250159261A (ko) | 2023-03-24 | 2025-11-10 | 상하이 제유 파마슈티칼 컴퍼니 리미티드 | Wrn 헬리케이스 억제제로서의 화합물 |
| TW202438062A (zh) * | 2023-03-24 | 2024-10-01 | 大陸商上海濟煜醫藥科技有限公司 | 作爲wrn解旋酶抑制劑的雜環類化合物及其製備方法和應用 |
| EP4698534A1 (en) * | 2023-04-21 | 2026-02-25 | Nimbus Wadjet, Inc. | [1,2,4]triazolo[1,5-a]pyrimidinone wrn inhibitors |
| WO2024222677A1 (zh) * | 2023-04-25 | 2024-10-31 | 苏州浦合医药科技有限公司 | Wrn抑制剂 |
| CN116496223A (zh) * | 2023-04-26 | 2023-07-28 | 福建凯昕药业有限公司 | 5-溴-4-甲基-2-三氟甲基嘧啶的一种制备方法 |
| WO2024230828A1 (en) * | 2023-05-11 | 2024-11-14 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| AR132698A1 (es) * | 2023-05-17 | 2025-07-23 | Insilico Medicine Ip Ltd | DERIVADOS ESPIRO COMO INHIBIDORES DE LA HELICASA TIPO RecQ DEL SÍNDROME DE WERNER (WRN) |
| TW202510857A (zh) * | 2023-06-01 | 2025-03-16 | 英商葛蘭素史密斯克藍智慧財產權有限公司 | 化合物及其用途 |
| UY40772A (es) | 2023-06-08 | 2024-12-31 | Nimbus Wadjet Inc | Inhibidores de wrn |
| CN121487950A (zh) * | 2023-06-09 | 2026-02-06 | 林伯士瓦吉特公司 | 噁唑并吡啶-7(4h)-酮wrn抑制剂 |
| CN121358739A (zh) * | 2023-06-12 | 2026-01-16 | 抟相医药(上海)有限公司 | 新型化合物，包含其的组合物及其用途 |
| WO2024259048A2 (en) * | 2023-06-13 | 2024-12-19 | Nimbus Wadjet, Inc. | Thiazolopyridin-7(4h)-one wrn inhibitors |
| CN121399130A (zh) * | 2023-06-15 | 2026-01-23 | 勤浩医药(苏州)股份有限公司 | 稠环化合物、包含其的药物组合物及其用途 |
| TW202506111A (zh) * | 2023-07-07 | 2025-02-16 | 美商林伯士瓦吉特公司 | 三唑并wrn抑制劑 |
| WO2025014846A1 (en) * | 2023-07-11 | 2025-01-16 | Merck Sharp & Dohme Llc | Spirocyclic wrn helicase inhibitors |
| WO2025021148A1 (zh) * | 2023-07-27 | 2025-01-30 | 贝达药业股份有限公司 | Wrn抑制剂及其药物组合物和应用 |
| WO2025026382A1 (zh) * | 2023-08-01 | 2025-02-06 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025040168A1 (en) * | 2023-08-24 | 2025-02-27 | Zai Lab (Shanghai) Co., Ltd. | Spiro-triazolopyrimidine analogues as wrn inhibitors and uses thereof |
| AU2024332123A1 (en) * | 2023-08-29 | 2026-02-26 | Eikon Therapeutics, Inc. | Compositions comprising werner syndrome helicase inhibitors and methods of using the same |
| CN119528909A (zh) * | 2023-08-29 | 2025-02-28 | 上海科恩泰生物医药科技有限公司 | 一种抑制wrn解旋酶的双杂环衍生物、含其的药物组合物及其应用 |
| AU2024335616A1 (en) * | 2023-09-08 | 2026-03-12 | Moma Therapeutics, Inc. | Tricyclic derivatives and related uses |
| WO2025067429A1 (en) * | 2023-09-28 | 2025-04-03 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025073792A1 (en) | 2023-10-02 | 2025-04-10 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| CN121646596A (zh) * | 2023-10-12 | 2026-03-10 | 楚浦创制（武汉）医药科技有限公司 | 吡啶酮并环类衍生物及其应用 |
| WO2025087274A1 (zh) * | 2023-10-27 | 2025-05-01 | 浙江海正药业股份有限公司 | 氮杂双环类衍生物及其制备方法和用途 |
| WO2025106949A1 (en) * | 2023-11-16 | 2025-05-22 | Radd Pharmaceuticals, Inc. | Wrn inhibitors |
| WO2025106693A1 (en) * | 2023-11-16 | 2025-05-22 | Eikon Therapeutics, Inc. | Methods and compositions for treating cancers with high microsatellite instability levels |
| CN117865963B (zh) * | 2023-12-15 | 2026-02-24 | 上海凌凯科技股份有限公司 | 一种嘧啶酮衍生物的合成方法及嘧啶酮衍生物 |
| WO2025137599A1 (en) * | 2023-12-21 | 2025-06-26 | Nimbus Wadjet, Inc. | Wrn inhibitors |
| WO2025130971A1 (zh) * | 2023-12-21 | 2025-06-26 | 勤浩医药（苏州）有限公司 | 稠环化合物、包含其的药物组合物及其用途 |
| WO2025137640A1 (en) * | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025133395A1 (en) | 2023-12-22 | 2025-06-26 | Forx Therapeutics Ag | Bicyclic (hetero)arylene wrn inhibitory compounds |
| TW202542158A (zh) * | 2023-12-29 | 2025-11-01 | 大陸商勤浩醫藥(蘇州)有限公司 | 稠環化合物、包含其的藥物組合物及其用途 |
| TW202539684A (zh) * | 2024-01-15 | 2025-10-16 | 大陸商上海齊魯製藥研究中心有限公司 | 一種三唑並嘧啶類衍生物、其製備方法與應用 |
| WO2025152750A1 (zh) * | 2024-01-17 | 2025-07-24 | 成都微芯药业有限公司 | 双杂环wrn抑制剂、其制备方法及其应用 |
| CN120398919A (zh) * | 2024-02-01 | 2025-08-01 | 福石生物科技(合肥)有限公司 | 作为wrn抑制剂的螺环衍生物及其应用 |
| CN120424093A (zh) * | 2024-02-02 | 2025-08-05 | 中国科学院上海药物研究所 | 螺环类化合物、包含其的药物组合物及其用途 |
| WO2025162478A1 (en) * | 2024-02-04 | 2025-08-07 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2025172934A1 (en) | 2024-02-16 | 2025-08-21 | Janssen Pharmaceutica Nv | Triazolo[4,5-b]pyridine compounds useful as inhibitors of werner syndrome recq helicase (wrn) |
| WO2025180452A1 (zh) * | 2024-02-29 | 2025-09-04 | 南京再明医药有限公司 | Wrn抑制剂化合物及其应用 |
| WO2025191176A1 (en) | 2024-03-14 | 2025-09-18 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| TW202547484A (zh) | 2024-04-10 | 2025-12-16 | 瑞士商諾華公司 | 藥物組合及其用途 |
| WO2025223388A1 (zh) * | 2024-04-22 | 2025-10-30 | 南京再明医药有限公司 | 三并环类化合物及其应用 |
| WO2025223396A1 (en) * | 2024-04-22 | 2025-10-30 | 3H Pharmaceuticals Co., Ltd. | Fused tricyclic compounds and methods of use thereof |
| WO2025232693A1 (en) * | 2024-05-08 | 2025-11-13 | Nuphase Therapeutics (Shanghai) Limited., Co. | Novel compounds, compositions comprising the same and uses thereof |
| WO2025237361A1 (zh) * | 2024-05-16 | 2025-11-20 | 海思科医药集团股份有限公司 | 一种氧代三并环类衍生物及其在医药上的应用 |
| WO2025252190A1 (en) * | 2024-06-07 | 2025-12-11 | Cullgen Inc. | Targeted degraders of werner syndrome recq helicase |
| WO2025261486A1 (en) * | 2024-06-22 | 2025-12-26 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
| WO2026006796A1 (en) * | 2024-06-27 | 2026-01-02 | Eikon Therapeutics, Inc. | Compositions comprising werner syndrome helicase inhibitors and methods of using the same |
| CN121226261A (zh) * | 2024-06-28 | 2025-12-30 | 武汉人福创新药物研发中心有限公司 | 作为wrn抑制剂的含芳香环化合物及其应用 |
| WO2026003380A1 (en) | 2024-06-28 | 2026-01-02 | Forx Therapeutics Ag | Wrn inhibitory compounds |
| CN121426817A (zh) * | 2024-07-10 | 2026-01-30 | 广州科恩泰生物医药科技有限公司 | 一种抑制wrn解旋酶的含氮杂环衍生物、含其的药物组合物及其应用 |
| WO2026028180A1 (en) | 2024-08-01 | 2026-02-05 | Janssen Pharmaceutica Nv | [1,2,4]triazolo[1,5-a]pyrimidin-7(4h)-one derivatives useful as inhibitors of wrn |
| WO2026028179A1 (en) | 2024-08-01 | 2026-02-05 | Janssen Pharmaceutica Nv | Compounds useful as inhibitors of werner syndrome recq helicase (wrn) |
| WO2026039591A1 (en) * | 2024-08-15 | 2026-02-19 | Synnovation Therapeutics, Inc. | Compounds comprising a fused tetracyclic group useful as wrn inhibitors |
| CN119431379A (zh) * | 2024-11-06 | 2025-02-14 | 中国药科大学 | Wrn降解剂及其制备方法和应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| AU2007289232A1 (en) * | 2006-08-29 | 2008-03-06 | President And Fellows Of Harvard College | Therapeutic methods using WRN binding molecules |
| US8173661B2 (en) | 2006-11-08 | 2012-05-08 | The Rockefeller University | Alpha-IIB-beta-3 inhibitors and uses thereof |
| SG173617A1 (en) * | 2009-02-11 | 2011-09-29 | Univ California | Toll-like receptor modulators and treatment of diseases |
| US20160002247A1 (en) * | 2013-03-01 | 2016-01-07 | The University Of Tokyo | 8-substituted imidazopyrimidinone derivative having autotaxin inhibitory activity |
| ES2716685T3 (es) | 2014-01-24 | 2019-06-14 | Dana Farber Cancer Inst Inc | Moléculas de anticuerpo para PD-1 y usos de las mismas |
| WO2018229683A1 (en) * | 2017-06-15 | 2018-12-20 | Novartis Ag | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |
| WO2019016772A2 (en) | 2017-07-21 | 2019-01-24 | Novartis Ag | COMPOSITIONS AND METHODS FOR TREATING CANCER |
| US12246004B2 (en) | 2018-06-04 | 2025-03-11 | The Broad Institute, Inc. | Therapeutic treatment of microsatellite unstable cancers |
| US20210371855A1 (en) * | 2018-06-15 | 2021-12-02 | Ideaya Biosciences, Inc. | Methods of inhibiting proliferative cells |
| US11945803B2 (en) | 2018-08-07 | 2024-04-02 | Tosk, Inc. | Modulators of RAS GTPase |
| WO2020041756A1 (en) | 2018-08-23 | 2020-02-27 | Foghorn Therapeutics Inc. | Methods of treating cancer |
| CN112409331B (zh) | 2019-08-21 | 2024-02-20 | 上海翰森生物医药科技有限公司 | 杂环类衍生物抑制剂、其制备方法和应用 |
| CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
| US20230348518A1 (en) * | 2020-10-05 | 2023-11-02 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Helicase inhibitors for treatment of medical disorders |
-
2022
- 2022-05-24 AR ARP220101380A patent/AR125966A1/es unknown
- 2022-05-24 TW TW111119316A patent/TW202313616A/zh unknown
- 2022-05-24 KR KR1020237044267A patent/KR20240013168A/ko active Pending
- 2022-05-24 EP EP22729790.0A patent/EP4347596A1/en active Pending
- 2022-05-24 BR BR112023024551A patent/BR112023024551A2/pt unknown
- 2022-05-24 PY PY202202240956A patent/PY2240956A/es unknown
- 2022-05-24 CR CR20230616A patent/CR20230616A/es unknown
- 2022-05-24 AU AU2022279728A patent/AU2022279728A1/en active Pending
- 2022-05-24 PE PE2023003130A patent/PE20240587A1/es unknown
- 2022-05-24 JP JP2023572685A patent/JP7753397B2/ja active Active
- 2022-05-24 CN CN202280035572.6A patent/CN117425657A/zh active Pending
- 2022-05-24 CA CA3219799A patent/CA3219799A1/en active Pending
- 2022-05-24 MX MX2023013892A patent/MX2023013892A/es unknown
- 2022-05-24 UY UY0001039786A patent/UY39786A/es unknown
- 2022-05-24 WO PCT/IB2022/054850 patent/WO2022249060A1/en not_active Ceased
- 2022-05-24 PH PH1/2023/553140A patent/PH12023553140A1/en unknown
- 2022-05-24 IL IL308229A patent/IL308229A/en unknown
- 2022-05-25 US US17/824,407 patent/US11878973B2/en active Active
-
2023
- 2023-11-02 ZA ZA2023/10237A patent/ZA202310237B/en unknown
- 2023-11-10 US US18/506,164 patent/US20240360118A1/en active Pending
- 2023-11-22 DO DO2023000256A patent/DOP2023000256A/es unknown
- 2023-11-23 CL CL2023003489A patent/CL2023003489A1/es unknown
- 2023-11-23 JO JOJO/P/2023/0304A patent/JOP20230304A1/ar unknown
- 2023-12-21 CO CONC2023/0018119A patent/CO2023018119A2/es unknown
- 2023-12-21 EC ECSENADI202395674A patent/ECSP23095674A/es unknown
-
2025
- 2025-10-01 JP JP2025165245A patent/JP2026021315A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024522345A (ja) | 2024-06-18 |
| DOP2023000256A (es) | 2024-01-31 |
| KR20240013168A (ko) | 2024-01-30 |
| JOP20230304A1 (ar) | 2023-11-23 |
| TW202313616A (zh) | 2023-04-01 |
| US20240360118A1 (en) | 2024-10-31 |
| US11878973B2 (en) | 2024-01-23 |
| WO2022249060A1 (en) | 2022-12-01 |
| ZA202310237B (en) | 2025-02-26 |
| US20230046859A1 (en) | 2023-02-16 |
| CN117425657A (zh) | 2024-01-19 |
| BR112023024551A2 (pt) | 2024-02-15 |
| CR20230616A (es) | 2024-05-06 |
| CA3219799A1 (en) | 2022-12-01 |
| AR125966A1 (es) | 2023-08-30 |
| CL2023003489A1 (es) | 2024-06-28 |
| PY2240956A (es) | 2023-11-09 |
| IL308229A (en) | 2024-01-01 |
| CO2023018119A2 (es) | 2023-12-29 |
| PE20240587A1 (es) | 2024-03-21 |
| JP7753397B2 (ja) | 2025-10-14 |
| AU2022279728A1 (en) | 2023-11-16 |
| ECSP23095674A (es) | 2024-01-31 |
| PH12023553140A1 (en) | 2024-04-29 |
| EP4347596A1 (en) | 2024-04-10 |
| JP2026021315A (ja) | 2026-02-10 |
| MX2023013892A (es) | 2023-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39786A (es) | Derivados de Triazolopirimidina y su uso en el Tratamiento de Enfermedades | |
| CL2025001072A1 (es) | Compuestos tricíclicos; composición farmacéutica; uso para tratar cáncer. | |
| MX2022001908A (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina. | |
| CO2022001094A2 (es) | Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas | |
| ECSP22047876A (es) | Derivados de pirazolilo ?tiles como agentes anticancer?genos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| AR132802A1 (es) | 2-amino-3-cianotiofenos con anillos espirocíclicos y derivados para el tratamiento del cáncer | |
| CO6390066A2 (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| CR20200334A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| UY32462A (es) | Derivados de bifenilo novedosos para el tratamiento de infección por virus de hepatitis c 644 | |
| CR20110270A (es) | Piriloxi-indoles Inhibidores del VEGF-R2 y Uso de los Mismos para el Tratamiento de Enfermedades | |
| UY29633A1 (es) | Derivados de oxindol | |
| DOP2015000169A (es) | Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas | |
| UY29469A1 (es) | Compuestos sulfoximino-macrocíclicos y sus sales, composiciones farmacéuticas que comprenden dichos compuestos, métodos de preparación y usos de los mismos. | |
| ECSP19026973A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| AR054347A1 (es) | Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion | |
| UY39181A (es) | COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO | |
| CO2023017669A2 (es) | Terapia combinada anti-vhc ventajosa | |
| DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso | |
| CO2023012702A2 (es) | Derivados de diazepina útiles en el tratamiento de clostridium difficile | |
| CO2025005872A2 (es) | Compuestos tricíclicos y sus usos | |
| UY28387A1 (es) | Compuestos novedosos | |
| UY39532A (es) | Compuestos de (aza)benzotiazolil-pirazol sustituidos |